Febuxostat: Drug information

For additional information see "Febuxostat: Patient drug information"

For abbreviations, symbols, and age group definitions show table

ALERT: US Boxed Warning

Cardiovascular death:

Gout patients with established cardiovascular (CV) disease treated with febuxostat had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study. Consider the risks and benefits of febuxostat when deciding to prescribe or continue patients on febuxostat. Febuxostat should only be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Brand Names: US

Uloric

Brand Names: Canada

AURO-Febuxostat;
JAMP Febuxostat;
MAR-Febuxostat;
TEVA-Febuxostat;
Uloric [DSC]

Pharmacologic Category

Antigout Agent;
Xanthine Oxidase Inhibitor

Dosing: Adult

Note: Urate-lowering therapy (ULT) may be initiated during a gout flare or after the flare subsides; concomitant pharmacologic prophylaxis with colchicine, nonsteroidal anti-inflammatory drugs, or a glucocorticoid is recommended for at least the first 3 to 6 months to decrease flare activity (Ref).

Hyperuricemia

Hyperuricemia: Oral: Initial: 40 mg once daily; may increase to 80 mg once daily in patients who do not achieve a serum uric acid level <6 mg/dL after 2 weeks. The dose may be increased further to 120 mg once daily if clinically indicated (Ref).

Tumor lysis syndrome, prevention

Tumor lysis syndrome, prevention (alternative therapy) (off-label use): Patients at intermediate or high risk for tumor lysis syndrome (TLS):

Note: Aggressive IV hydration should always be initiated prior to cytotoxic therapy in patients at elevated risk for TLS (Ref). The optimal dose of febuxostat for the prevention of TLS is not yet established (Ref).

Oral: 40 to 60 mg once daily (Ref) or 120 mg once daily (Ref). Begin 1 to 2 days before the start of chemotherapy and continue for up to 14 days until normalization of laboratory evidence of TLS (eg, serum uric acid, serum lactate dehydrogenase) (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

CrCl ≥30 mL/minute: No dosage adjustment necessary (Ref).

CrCl <30 mL/minute: Initial: 20 to 40 mg once daily (Ref). Note: Observational studies in patients with hyperuricemia have reported safety and tolerability of 60 and 80 mg/day; a careful titration may be considered in patients unresponsive to standard doses (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (highly protein bound): Initial: 20 to 40 mg once daily; no supplemental dose necessary (Ref). Note: A small, retrospective, observational study in patients with hyperuricemia reported safety and tolerability of doses up to 80 mg/day (Ref); a careful titration may be considered in patients unresponsive to standard doses (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (highly protein bound): Initial: 20 to 40 mg once daily (Ref). Note: A small, retrospective, observational study in patients with hyperuricemia reported safety and tolerability of doses up to 80 mg/day (Ref); a careful titration may be considered in patients unresponsive to standard doses (Ref).

CRRT: Dose as for CrCl <30 mL/minute (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration ): Dose as for CrCl <30 mL/minute (Ref).

Dosing: Hepatic Impairment: Adult

Preexisting hepatic impairment:

Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.

Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution.

Hepatotoxicity during treatment:

ALT or AST >3 times ULN (in the clinical context of potential liver injury [eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice]): Interrupt febuxostat therapy and evaluate. Do not reinitiate febuxostat if liver injury is confirmed or no alternate etiology for liver test abnormalities is identified.

ALT or AST >3 times ULN and serum total bilirubin >2 times ULN without alternative etiology: Permanently discontinue.

Dosing: Adjustment for Toxicity: Adult

Hypersensitivity or severe skin reactions: Discontinue febuxostat if hypersensitivity or severe skin reactions develop.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions (Significant): Considerations

Acute gout attacks

Acute gout attacks have been reported during the early stages of urate-lowering therapy, including febuxostat, even when normal or optimal serum uric acid levels have been attained. Gout attacks generally decrease in duration and severity after several months of urate-lowering therapy (Ref)

Mechanism: Dose-related; related to the pharmacologic action and innate immune response. Decrease in serum urate leads to the dissolution of monosodium urate crystal deposits and dispersion of crystals. Gout flares occur via complement activation and direct interaction of monosodium urate crystals with neutrophils and monocytes/macrophages (Ref).

Onset: Varied; most likely to occur within first 6 months of treatment (Ref); risk is lower after 1 year of treatment (Ref).

Risk factors:

• Early in course of treatment (Ref)

• Initiating urate-lowering treatment without concurrent gout flare prophylaxis (Ref)

• Withdrawal of anti-inflammatory gout flare prophylaxis <3 months after initiation (Ref)

• Uric acid >6 mg/dL during treatment (Ref)

• Rapid decreases and/or greater reduction in uric acid (Ref)

• Presence of tophi (Ref)

Hypersensitivity reactions (delayed)

Delayed hypersensitivity reactions may occur, including morbilliform skin rash and severe cutaneous adverse reactions (SCARs) (Ref). SCARs include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, and toxic epidermal necrolysis (Ref). Other delayed reactions include eosinophilic polymyositis (Ref).

Mechanism: Immunologic; delayed hypersensitivity reactions, including morbilliform drug eruptions and SCARs are T-cell-mediated (Ref).

Onset: Delayed hypersensitivity reactions: Varied; usually occur within 2 months after initiation with a median of 21 days (Ref).

Risk factors:

• Cross-reactivity between allopurinol and febuxostat: No suspected cross-reactivity based on structural similarity; febuxostat is a non-purine xanthine oxidase inhibitor (Ref). Unlike allopurinol SCAR reactions, there is no known HLA association and no association with HLA-B*58:01 (Ref). Most patients with a history of a hypersensitivity reaction to allopurinol can tolerate febuxostat (Ref). While there may be increased risk of a skin reaction with febuxostat in patients with a history of reactions to allopurinol, the basis of this may not be cross-reactivity. Patients with allopurinol SCAR reactions, such as DRESS, can have relapse of the rash in the absence of the drug following the reaction (Ref). In one study, febuxostat did not differ significantly from allopurinol in the risk of hypersensitivity reactions (Ref).

Major cardiovascular events

Major adverse cardiovascular events (MACE), including cardiovascular death and hospitalizations due to heart failure (HF), have been reported in association with febuxostat (Ref). In contrast, other studies have not found an elevated risk of MACE (Ref). Guidelines recommend considering alternative urate-lowering therapy in patients with a history of cardiovascular disease (CVD) or a new CVD-related event (Ref). There may be an increased risk of CV events with febuxostat compared to allopurinol; although, some studies show similar risk (Ref).

Mechanism: Unknown; xanthine oxidase inhibition may disrupt the activity of nitric oxide synthase, which can reduce coronary blood flow and cause ineffective excitation contraction myocardial coupling. Additionally, the chemical activities of a non–purine-like medication (febuxostat) compared to a purine analog (allopurinol) may contribute to less cardiovascular (CV) protective effects (Ref). Rebound hyperuricemia at the time of drug discontinuation may lead to acute inflammation caused by monosodium urate crystals that deposit within the CV system, as well as endothelial dysfunction and oxidative stress (Ref).

Onset: Varied; may occur at any point during treatment. Increased incidence of CV events, including CV death, have also been observed within 6 months after discontinuation (Ref).

Risk factors:

• History of CVD (Ref)

• Female patients may have an increased risk of HF hospitalization (Ref)

• Discontinuation of febuxostat; and after discontinuation, fluctuations in uric acid levels, age, and body mass index (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

1% to 10%:

Dermatologic: Skin rash (0.5% to 2%) (table 1)Skin Rash

**Febuxostat: Adverse Reaction: Skin Rash**
Drug (Febuxostat)	Comparator (Allopurinol)	Placebo	Dose	Number of Patients (Febuxostat)	Number of Patients (Allopurinol)	Number of Patients (Placebo)
2%	2%	0.7%	80 mg daily	1,279	1,277	134
0.5%	2%	0.7%	40 mg daily	757	1,277	134

Gastrointestinal: Nausea (1%)

Hepatic: Hepatic insufficiency (5% to 7%), increased serum alanine aminotransferase (3%), increased serum aspartate aminotransferase (2%)

Neuromuscular & skeletal: Arthralgia (≤1%)

<1%:

Cardiovascular: Angina pectoris, atrial fibrillation, atrial flutter, chest pain, ECG abnormality, edema, flushing, heart murmur, hypertension, hypotension, increased serum creatine kinase, palpitations, sinus bradycardia, tachycardia

Dermatologic: Abnormal skin odor, alopecia, dermatitis, ecchymoses, eczema, exfoliation of skin, hair discoloration, hyperhidrosis, pruritus, skin discoloration, skin lesion, skin photosensitivity, urticaria (including dermographism)

Endocrine & metabolic: Decreased libido, decreased serum bicarbonate, dehydration, diabetes mellitus, gynecomastia, hirsutism, hot flash, hypercholesterolemia, hyperglycemia, hypertriglyceridemia, hypokalemia, increased lactate dehydrogenase, increased LDL cholesterol, increased serum potassium, increased serum sodium, increased thirst, increased thyroid stimulating hormone level, weight gain, weight loss

Gastrointestinal: Abdominal distention, abdominal pain, anorexia, cholecystitis, cholelithiasis, constipation, decreased appetite, dysgeusia, dyspepsia, flatulence, frequent bowel movements, gastric hyperacidity, gastritis, gastroesophageal reflux disease, gastrointestinal distress, gingival pain, hematemesis, hematochezia, increased appetite, increased serum amylase, oral mucosa ulcer, pancreatitis, peptic ulcer, vomiting, xerostomia

Genitourinary: Decreased urine output, erectile dysfunction, hematuria, increased urine output, mastalgia, pollakiuria, prostate specific antigen increase, proteinuria, urinary incontinence, urinary urgency

Hematologic & oncologic: Anemia, blood coagulation test abnormality, bruise, immune thrombocytopenia, increased MCV, leukocytosis, leukocyturia, leukopenia, lymphocytopenia, neutropenia, pancytopenia, petechia, prolonged partial thromboplastin time, prolonged prothrombin time, purpuric disease, splenomegaly, thrombocytopenia

Hepatic: Hepatitis, hepatomegaly, increased serum alkaline phosphatase, liver steatosis

Hypersensitivity: Angioedema

Infection: Herpes zoster infection

Nervous system: Abnormal electroencephalogram, abnormal gait, agitation, altered sense of smell (decreased), anxiety, asthenia, balance impairment, cerebral infarction (lacunar), cerebrovascular accident, decreased mental acuity, depression, drowsiness, fatigue, feeling abnormal, Guillain-Barré syndrome, headache, hemiparesis, hypertonia, hypoesthesia, insomnia, irritability, lethargy, migraine, myasthenia, nervousness, pain, panic attack, paresthesia, personality changes, transient ischemic attacks, tremor, vertigo

Neuromuscular & skeletal: Arthritis, increased creatine phosphokinase in blood specimen, joint stiffness, joint swelling, muscle rigidity, muscle spasm, muscle twitching, musculoskeletal pain, myalgia

Ophthalmic: Blurred vision

Otic: Deafness, tinnitus

Renal: Casts in urine, increased blood urea nitrogen, increased serum creatinine, nephrolithiasis, renal failure syndrome

Respiratory: Bronchitis, cough, dry nose, dyspnea, epistaxis, flu-like symptoms, paranasal sinus hypersecretion, pharyngeal edema, respiratory congestion, sneezing, throat irritation, upper respiratory tract infection

Miscellaneous: Mass

Frequency not defined: Endocrine & metabolic: Acute gout attack

Postmarketing:

Dermatologic: Erythema multiforme, fixed drug eruption (Oda 2016), Stevens-Johnson syndrome, toxic epidermal necrolysis (Han 2020)

Hematologic & oncologic: Agranulocytosis (Poh 2017), eosinophilia

Hepatic: Hepatic failure, hepatic injury (acute) (Bohm 2016), jaundice (Bohm 2016)

Hypersensitivity: Anaphylaxis, drug reaction with eosinophilia and systemic symptoms (Paschou 2016)

Nervous system: Psychotic symptoms (including aggressive behavior)

Neuromuscular & musculoskeletal: Polymyositis (eosinophilic) (Chahine 2017), rhabdomyolysis (Kang 2014)

Renal: Interstitial nephritis

Contraindications

Concurrent use with azathioprine or mercaptopurine.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to febuxostat or any component of the formulation.

Warnings/Precautions

Disease-related concerns:

• Secondary hyperuricemia: Use in secondary hyperuricemia has not been studied; avoid use in patients at increased risk of urate formation (eg, malignancy and its treatment; Lesch-Nyhan syndrome).

Dosage forms specific issues:

• Lactose: Contains lactose.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Uloric: 40 mg, 80 mg

Generic: 40 mg, 80 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Febuxostat Oral)

40 mg (per each): $8.65 - $12.38

80 mg (per each): $8.65 - $12.38

Tablets (Uloric Oral)

40 mg (per each): $13.20

80 mg (per each): $13.20

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Uloric: 80 mg [DSC] [contains fd&c blue #1 (brilliant blue), fd&c blue #2 (indigotine,indigo carmine), quinoline (d&c yellow #10) aluminum lake]

Generic: 80 mg

Administration: Adult

Oral: Administer with or without meals or antacids.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021856s015lbl.pdf#page=19, must be dispensed with this medication.

Use: Labeled Indications

Hyperuricemia: Chronic management of hyperuricemia in patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable

Limitations of use: Not recommended for treatment of asymptomatic hyperuricemia.

Use: Off-Label: Adult

Tumor lysis syndrome, prevention (alternative therapy)

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2C8 (minor), CYP2C9 (minor), UGT1A1, UGT1A3, UGT1A9, UGT2B7; Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits BCRP/ABCG2

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpelisib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Alpelisib. Management: Avoid coadministration of BCRP/ABCG2 inhibitors and alpelisib due to the potential for increased alpelisib concentrations and toxicities. If coadministration cannot be avoided, closely monitor for increased alpelisib adverse reactions. Risk D: Consider therapy modification

AzaTHIOprine: Febuxostat may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Febuxostat may increase the serum concentration of AzaTHIOprine. Risk X: Avoid combination

Belumosudil: May increase the serum concentration of UGT1A1 Substrates. Management: Avoid coadministration of belumosudil with substrates of UGT1A1 for which minimal concentration increases can cause serious adverse effects. If coadministration is required, dose reductions of the UGT1A1 substrate may be required. Risk D: Consider therapy modification

Berotralstat: BCRP/ABCG2 Inhibitors may increase the serum concentration of Berotralstat. Management: Decrease the berotralstat dose to 110 mg daily when combined with BCRP inhibitors. Risk D: Consider therapy modification

Cladribine: BCRP/ABCG2 Inhibitors may increase the serum concentration of Cladribine. Management: Avoid concomitant use of BCRP inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration. Risk D: Consider therapy modification

Didanosine: Febuxostat may increase the serum concentration of Didanosine. Risk X: Avoid combination

Mercaptopurine: Febuxostat may increase the serum concentration of Mercaptopurine. Risk X: Avoid combination

Methotrexate: Febuxostat may enhance the adverse/toxic effect of Methotrexate. Risk C: Monitor therapy

Mitapivat: May decrease the serum concentration of UGT1A1 Substrates. Risk C: Monitor therapy

PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. Risk X: Avoid combination

Pegloticase: Febuxostat may enhance the adverse/toxic effect of Pegloticase. Specifically, Febuxostat may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. Risk X: Avoid combination

Rosuvastatin: Febuxostat may increase the serum concentration of Rosuvastatin. Management: Limit the dose of rosuvastatin to 20 mg daily when combined with febuxostat. Monitor closely for increased rosuvastatin effects/toxicities (eg, myalgias, rhabdomyolysis) when these agents are combined. Risk D: Consider therapy modification

Talazoparib: BCRP/ABCG2 Inhibitors may increase the serum concentration of Talazoparib. Risk C: Monitor therapy

Theophylline Derivatives: Febuxostat may increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated. Risk C: Monitor therapy

Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan. Risk X: Avoid combination

Ubrogepant: BCRP/ABCG2 Inhibitors may increase the serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 50 mg and second dose (at least 2 hours later if needed) of 50 mg when used with a BCRP inhibitor. Risk D: Consider therapy modification

Pregnancy Considerations

Adverse events were observed in some animal reproduction studies.

Breastfeeding Considerations

It is not known if febuxostat is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Monitoring Parameters

LFTs at baseline, periodically, and if signs/symptoms of hepatic injury (eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice). For gout, monitor serum uric acid levels (as early as 2 weeks after initiation, after each dosage titration), then every 6 months (symptomatic patients or tophi) or every 12 months (all patients on urate-lowering therapy, regardless of symptoms) (FitzGerald 2018). Monitor for signs/symptoms of cardiovascular events and signs/symptoms of hypersensitivity or severe skin reactions.

Reference Range

Uric acid, serum:

Adults:

Note: Reference ranges may vary depending on the laboratory.

Normal values: 3 to 7 mg/dL (SI: 178.5 to 416.5 micromole/L).

Goal during therapy: <6 mg/dL (SI: <357 micromole/L); <5 mg/dL (SI: <297.5 micromole/L) in patients with severe gout (eg, tophi, frequent attacks, chronic arthropathy) (EULAR [Richette 2017]). Levels <3 mg/dL (SI: <178.5 micromole/L) are not recommended long-term (EULAR [Richette 2017]).

Note: Serum uric acid values >7 mg/dL (SI: >416.5 micromole/L) do not necessarily represent clinical gout; the American College of Rheumatology clinical practice guidelines recommend against initiating pharmacologic management of asymptomatic hyperuricemia (ACR [FitzGerald 2020]).

Mechanism of Action

Selectively inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid thereby decreasing uric acid. At therapeutic concentration does not inhibit other enzymes involved in purine and pyrimidine synthesis.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: ≥49%

Distribution: V_ss: ~50 L

Protein binding: ~99%, primarily to albumin

Metabolism: Extensive conjugation via uridine diphosphate glucuronosyltransferases (UGTs) 1A1, 1A3, 1A9, and 2B7 and oxidation via cytochrome P450 (CYP) 1A2, 2C8, and 2C9 as well as non-P450 enzymes. Oxidation leads to formation of active metabolites (67M-1, 67M-2, 67M-4)

Half-life elimination: ~5 to 8 hours

Time to peak, plasma: 1 to 1.5 hours

Excretion: Urine (~49% mostly as metabolites, 3% as unchanged drug); feces (~45% mostly as metabolites, 12% as unchanged drug)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Sex: Following multiple oral doses, C_max and AUC are 30% and 14% higher in women than men, respectively.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Adenuric | Agout | Donifoxate | Febox | Uloric | Urifox | Zoxta;
(AR) Argentina: Febuloric | Febuxtat;
(AT) Austria: Adenuric | Feburo | Febuxostat +pharma | Febuxostat accord | Febuxostat aristo | Febuxostat genericon | Febuxostat ratiopharm | Febuxostat sandoz | Febuxostat stada;
(AU) Australia: Adenuric;
(BD) Bangladesh: Barif | Eburic | Febox | Febulas | Feburic | Febus | Febustat | Febux | Feluric | Fostat | Goustat | Goutil | Uristat | Urostat | Xanuric;
(BE) Belgium: Adenuric | Febuxostat ab | Febuxostat eg | Febuxostat mylan | Febuxostat sandoz;
(BG) Bulgaria: Adenuric | Druniler | Febustad | Febuxostat mylan | Febuxostat pharmascience | Febuxostat zentiva;
(CH) Switzerland: Adenuric;
(CN) China: Feng ding ning | Rui yang;
(CO) Colombia: Febuday;
(CZ) Czech Republic: Adenuric | Febul | Febuxostat accord | Febuxostat krka | Febuxostat msn | Febuxostat mylan | Febuxostat sandoz | Febuxostat zentiva | Urikostad;
(DE) Germany: Adenuric | Febuxostat 1a pharma | Febuxostat abz | Febuxostat accord | Febuxostat aristo | Febuxostat axiromed | Febuxostat beta | Febuxostat genevida | Febuxostat glenmark | Febuxostat heumann | Febuxostat mylan | Febuxostat ratiopharm | Febuxostat stada | Febuxostat Vivanta | Febuxostat zentiva;
(DO) Dominican Republic: Adenuric | Febuxtat | Staturic;
(EE) Estonia: Adenuric | Druniler | Febuxostat krka | Febuxostat mylan | Febuxostat zentiva;
(EG) Egypt: Andouristat | Donifoxate | Effecturin | Febumagictam | Feburic | Goutifade | Staturic | Unsiatem | Uricodrop | Xanthistop;
(ES) Spain: Adenuric | Febuxostat aristo | Febuxostat aurovitas | Febuxostat Bluepharma | Febuxostat cinfa | Febuxostat combix | Febuxostat kern pharma | Febuxostat krka | Febuxostat mabo | Febuxostat normon | Febuxostat ratiopharm | Febuxostat sandoz | Febuxostat stada | Febuxostat tecnigen | Febuxostat Teva | Febuxostat Viso farmaceutica | Febuxostat Vivanta | Gotaric;
(FI) Finland: Adenuric | Febuxostat accord | Febuxostat krka | Febuxostat medical valley;
(FR) France: Adenuric | Febuxostat accord | Febuxostat almus | Febuxostat arrow | Febuxostat biogran | Febuxostat cristers | Febuxostat eg | Febuxostat Evolugen | Febuxostat mylan | Febuxostat sandoz | Febuxostat teva sante | Febuxostat zentiva | Febuxostat zydus;
(GB) United Kingdom: Adenuric | Febuxostat dr reddys | Febuxostat ennogen;
(GR) Greece: Adenuric | Buxodem | Febuxostat/genepharm | Urichofeb;
(HK) Hong Kong: Feburic | Febuxostate pentafarma;
(HR) Croatia: Adenuric;
(HU) Hungary: Adenuric | Doluric | Feburo | Febuxostat krka | Febuxostat sandoz | Febuxostat stada;
(ID) Indonesia: Feburic | Ulostat;
(IE) Ireland: Adenuric | Febuxostat accord | Febuxostat clonmel | Febuxostat krka | Febuxostat mylan | Febuxostat pinewood | Febuxostat rowex;
(IN) India: Abustat | Arbon | Belosix | Buxoluric | Buxstat | Ciduric | Ebuxo | Fabric | Fabulas | Fabulon | Fabuzest | Factus | Fadvic | Fbt | FBX | Feb | Febiflo | Feblast | Feboxa | Febric | Febu | Febubest | Febucare | Febucip | Febudim | Febufix | Febuget | Febugood | Febulic | Febulog | Febumac | Febumost | Febunex | Febupath | Febuplus | Feburic | Febuset | Febusix | Febusta | Febustat | Febutac | Febutax | Febutaz | Febutek | Febuveda | Febuvel | Febuvib | Febuxoace | Febuxor | Febzeal | Febzen | Fexanto | Fexostat | Forgout | Foxstat | Fubox | Fubra | Furic | Goustat | Goutchek | Goutfree | Goxoi | Ibaxit | Normoric | Sebuxo | Segera | Ubax | Ubexa | Uricheck | Uricostat | Urif | Urifix | Urilact | Urinorm | Uristat | Urixoace | Urostat | Vilstat | X Feb | Xanbit | Xanfeb | Xanthinil | Xanthofex | Xanurix | Zurig;
(IT) Italy: Adenuric | Alphabux | Arbux | Dymauric | Febuxen | Febuxostat accord | Febuxostat aristo | Febuxostat aurobindo | Febuxostat doc generici | Febuxostat eg | Febuxostat krka | Febuxostat mylan | Febuxostat pensa | Febuxostat sandoz | Febuxostat tecnigen | Febuxostat Teva | Febuxostat zentiva | Gauti | Gottart;
(JO) Jordan: Adenuric | Fixuric | Tazotax | Zoxta;
(JP) Japan: Feburic | Febuxostat chemiphar | Febuxostat dsep | Febuxostat jg | Febuxostat kyorin | Febuxostat meiji | Febuxostat nipro | Febuxostat nissin | Febuxostat towa;
(KE) Kenya: Feblorika | Febo g | Febuday | Febus | Febustal | Febustat | Febuxo | Fexoberg | Goutgesic | Goutstat | Mebux | Presostat | Theofeb;
(KR) Korea, Republic of: Dongkoo febuxostat | Fabotat | Febot | Febroct | Febuctam | Feburic | Febuster | Febute | Febuxat | Febuxen | Febuxo | Febuxon | Febuxoric | Febuxsta | Febuxt | Febuxta | Febuxtin | Fecsot | Fegout | Feloxi | Ferad | Ferox | Fesorin | Festa | Fexod | Fexorin | Fexosta | Fexot | Fexotat | Gaobric | Hibric | Inno.n febuxostat | M buric | Nexota | Petrisen | Pharvis febuxostat | Reyon febuxostat | Samsung febuxostat | Seoul febuxostat | Staric | Uburic | Uniferic | Usoric | Yurigat | Yurigout | Yustat;
(LB) Lebanon: Adenuric | Agout | Febuxostat biogaran | Oxubat | Staburic;
(LT) Lithuania: Adenuric | Druniler | Febuxostat Teva | Febuxostat zentiva;
(LU) Luxembourg: Adenuric | Febuxostat eg | Febuxostat mylan;
(LV) Latvia: Adenuric | Druniler | Febuxostat krka | Febuxostat mylan | Febuxostat Teva | Febuxostat zentiva;
(MA) Morocco: Uloric;
(MX) Mexico: Turazive;
(MY) Malaysia: Adenuric | Febucip | Feburic | Febuton | Goutric | Uloric;
(NG) Nigeria: Donifoxate;
(NL) Netherlands: Adenuric | Febuxostat accord | Febuxostat Teva | Febuxostat xiromed;
(NO) Norway: Adenuric | Febuxostat accord | Febuxostat novadoz | Febuxostat sun | Uloric;
(NZ) New Zealand: Adenuric;
(PE) Peru: Staturic;
(PH) Philippines: Atenurix | Febsan | Febunol | Feburic | Furic | Mebux | Urica | Urinorm;
(PK) Pakistan: Abux | Adenuric | Arrestat | Baristat | Bexol | Biofeb | Burict | Buxo | Buxotat | Degouric | Deliro | Deuric | Dyxostat | Efco | Febex | Febhil | Febo | Feboric | Febstat | Febstate | Febucip | Febugout | Febulos | Febulus | Febunex | Febusave | Febustat | Febusyn | Febux | Febuxin | Frostat | Gouric | Hiloric | Louric | Reduric | Rid uric | Tyloric | Ulora | Uraxat | Urifab | Urifeb | Urigo | Uriguard | Uristat | Urizak | Uromin | Urostat | Vinfebo | Welbux | Welstate | Winstate | Xestat | Xostat | Zerogout | Zurich | Zurig | Zylosat | Zystat;
(PL) Poland: Adenuric | Denofix | Febuxostat accord | Febuxostat aurovitas | Febuxostat krka | Prohidna;
(PR) Puerto Rico: Uloric;
(PT) Portugal: Adenuric | Febuxostate aristo | Febuxostate bluepharma | Febuxostate farmoz | Febuxostate generis | Febuxostate tolife;
(QA) Qatar: Adenuric | Gouric | Zoxta | Zynostat;
(RO) Romania: Adenuric | Febuxostat aurobindo | Pexalit;
(RU) Russian Federation: Adenuric | Azurix;
(SA) Saudi Arabia: Adenuric | Agout | Goutex;
(SE) Sweden: Adenuric | Febuxostat accord | Febuxostat krka;
(SG) Singapore: Feburic;
(SI) Slovenia: Abuxar | Adenuric | Febuksostat teva;
(SK) Slovakia: Abuxar | Adenuric | Febuxostat sandoz;
(TH) Thailand: Feburic;
(TN) Tunisia: Adenuric;
(TR) Turkey: Adenuric;
(TW) Taiwan: Feburic | Febuton | Fetrin | Feuri | Forliton;
(UA) Ukraine: Adenuric | Efstat | Eurofeb | Febumax | Febuxostat xantis | Liquestia | Podafeb | Podagrat;
(UG) Uganda: Fabutas | Febuday | Febumac | Mebux;
(UY) Uruguay: Feburic;
(VN) Viet Nam: Febuxotid vk | Foribat | Opedulox | Uloxoric | Vaidilox | Vocanz;
(ZA) South Africa: Adenuric;
(ZM) Zambia: Xanurix

Abeles AM. Febuxostat hypersensitivity. J Rheumatol. 2012;39(3):659. doi:10.3899/jrheum.111161 [PubMed 22383358]
Al-Abdouh A, Khan SU, Barbarawi M, et al. Effects of febuxostat on mortality and cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc Innov Qual Outcomes. 2020;4(4):434-442. doi:10.1016/j.mayocpiqo.2020.04.012 [PubMed 32793871]
Bardin T, Chalès G, Pascart T, et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314-317. doi:10.1016/j.jbspin.2015.07.011 [PubMed 26709250]
Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585-591. doi:10.1080/15257770802136032 [PubMed 18600509]
Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461. doi:10.1056/NEJMoa050373 [PubMed 16339094]
Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V. Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther. 2019;44(4):525-533. doi:10.1111/jcpt.12839 [PubMed 30972811]
Bohm M, Vuppalanchi R, Chalasani N; Drug-Induced Liver Injury Network (DILIN). Febuxostat-induced acute liver injury. Hepatology. 2016;63(3):1047-1049. doi:10.1002/hep.28403 [PubMed 26679098]
Bruce SP. Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout. Ann Pharmacother. 2006;40(12):2187-2194. [PubMed 17132810]
Chahine G, Saleh K, Ghorra C, Khoury N, Khalife N, Fayad F. Febuxostat-associated eosinophilic polymyositis in marginal zone lymphoma. Joint Bone Spine. 2017;84(2):221-223. doi:10.1016/j.jbspin.2016.10.008 [PubMed 27955822]
Chen CH, Chen CB, Chang CJ, et al. Hypersensitivity and cardiovascular risks related to allopurinol and febuxostat therapy in Asians: a population-based cohort study and meta-analysis. Clin Pharmacol Ther. 2019;106(2):391-401. doi:10.1002/cpt.1377 [PubMed 30690722]
Cheng CL, Yen CT, Su CC, Lee CH, Huang CH, Yang YK. Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients. Front Cardiovasc Med. 2022;9:891606. doi:10.3389/fcvm.2022.891606 [PubMed 36035929]
Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957-1959. doi:10.3899/jrheum.110092 [PubMed 21724706]
Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert. Arthritis Rheumatol. 2018;70(11):1702-1709. doi:10.1002/art.40583 [PubMed 29869840]
Choi SY, Choi SW, Lee S, So MW, Oh JS, Lim DH. Efficacy and tolerability of febuxostat in gout patients on dialysis. Intern Med J. 2021;51(3):348-354. doi:10.1111/imj.14776 [PubMed 32043690]
Chou HY, Chen CB, Cheng CY, et al. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). J Clin Pharm Ther. 2015;40(6):689-692. doi:10.1111/jcpt.12322 [PubMed 26365588]
Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-2778. doi:10.1200/JCO.2007.15.0177 [PubMed 18509186]
Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamariz L. Febuxostat and cardiovascular events: a systematic review and meta-analysis. Int J Rheumatol. 2019;2019:1076189. doi:10.1155/2019/1076189 [PubMed 30863448]
Deng H, Zhang BL, Tong JD, Yang XH, Jin HM. Febuxostat use and risks of cardiovascular disease events, cardiac death, and all-cause mortality: metaanalysis of randomized controlled trials. J Rheumatol. 2021;48(7):1082-1089. doi:10.3899/jrheum.200307 [PubMed 32801136]
Di Paolo C, Minetti S, Mineni M, et al. Desensitization to febuxostat: report of two cases. J Allergy Clin Immunol Pract. 2015;3(4):633-636. doi:10.1016/j.jaip.2015.01.022 [PubMed 25758914]
Expert opinion. Senior Obesity EditorialTeam: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD,BPharm (Hons), B App Sc, FSHP, FISAC.
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180 [PubMed 32391934]
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879-895. doi:10.1002/art.41247 [PubMed 32390306]
FitzGerald JD, Mikuls TR, Neogi T, et al. Development of the American College of Rheumatology electronic clinical quality measures for gout. Arthritis Care Res (Hoboken). 2018;70(5):659-671. doi:10.1002/acr.23500 [PubMed 29649348]
Gao L, Wang B, Pan Y, Lu Y, Cheng R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. Clin Cardiol. 2021;44(7):907-916. doi:10.1002/clc.23643 [PubMed 34013998]
Ghang BZ, Lee JS, Choi J, Kim J, Yoo B. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial. RMD Open. 2022;8(2):e001944. doi:10.1136/rmdopen-2021-001944 [PubMed 35732345]
Guan X, Zhang S, Liu J, et al. Cardiovascular safety of febuxostat and allopurinol in patients with gout: a meta-analysis. Front Pharmacol. 2022;13:998441. doi:10.3389/fphar.2022.998441 [PubMed 36249825]
Han P, Hu L. Febuxostat-induced toxic epidermal necrolysis. Am J Ther. 2020;10.1097/MJT.0000000000001256. doi:10.1097/MJT.0000000000001256 [PubMed 33021532]
Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96(1-2):90-98. doi: 10.1159/000434633. [PubMed 26183164]
Kang EH. Considerations for choosing first-line urate-lowering treatment in older patients with comorbid conditions. Drugs Aging. 2022;39(12):923-933. doi:10.1007/s40266-022-00986-3 [PubMed 36437395]
Kang EH, Choi HK, Shin A, et al. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology (Oxford). 2019;58(12):2122-2129. doi:10.1093/rheumatology/kez189 [PubMed 31098635]
Kang Y, Kim MJ, Jang HN, et al. Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. J Clin Pharm Ther. 2014;39(3):328-330. doi:10.1111/jcpt.12144 [PubMed 24612195]
Kim SH, Lee SY, Kim JM, Son CN. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020;35(4):998-1003. doi:10.3904/kjim.2018.423 [PubMed 30959584]
Koenig D, Royer C, Azar A. Successful desensitization to febuxostat in a patient with hypersensitivity to allopurinol and febuxostat and review of the literature. J Clin Rheumatol. 2021;27(8S):S432-S433. doi:10.1097/RHU.0000000000001296 [PubMed 31977653]
Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;53(11):1920-1926. doi:10.1093/rheumatology/keu157 [PubMed 24758886]
Lien YH, Logan JL. Cross-reactions between allopurinol and febuxostat. Am J Med. 2017;130(2):e67-e68. doi:10.1016/j.amjmed.2016.08.042 [PubMed 27667702]
Lim DH, Oh JS, Ahn SM, et al. Febuxostat in hyperuricemic patients with advanced CKD. Am J Kidney Dis. 2016;68(5):819-821. doi:10.1053/j.ajkd.2016.07.001 [PubMed 27503183]
Lin CW, Huang WI, Chao PH, Chen WW, Hsiao FY. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: a nationwide study. Int J Clin Pract. 2019;73(5):e13316. doi:10.1111/ijcp.13316 [PubMed 30681751]
Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745-1757. doi:10.1016/S0140-6736(20)32234-0 [PubMed 33181081]
Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22-34. doi:10.1097/00045391-200501000-00005 [PubMed 15662289]
Oda T, Sawada Y, Ohmori S, et al. Fixed drug eruption-like macules caused by febuxostat. Eur J Dermatol. 2016;26(4):412-413. doi:10.1684/ejd.2016.2796 [PubMed 27211520]
Paschou E, Gavriilaki E, Papaioannou G, Tsompanakou A, Kalaitzoglou A, Sabanis N. Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease?. Eur Ann Allergy Clin Immunol. 2016;48(6):251-255. [PubMed 27852432]
Poh XE, Lee CT, Pei SN. Febuxostat-induced agranulocytosis in an end-stage renal disease patient: A case report. Medicine (Baltimore). 2017;96(2):e5863. doi:10.1097/MD.0000000000005863 [PubMed 28079821]
Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(1):58-68. doi:10.7326/M16-0570 [PubMed 27802508]
Quilis N, Vela P, Blanco Cáceres BA, et al. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. Ann Rheum Dis. 2022;81(7):e124. doi:10.1136/annrheumdis-2020-218226 [PubMed 32616605]
Refer to manufacturer's labeling.
Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. [PubMed 27457514]
Saag KG, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. Arthritis Rheumatol. 2019;71(1):143-153. doi:10.1002/art.40685 [PubMed 30073793]
Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68(8):2035-2043. doi:10.1002/art.39654 [PubMed 26894653]
Sawada S, Kajiyama K, Shida H, et al. Cardiovascular risk of urate-lowering drugs: a study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Clin Transl Sci. 2023;16(2):206-215. doi:10.1111/cts.13439 [PubMed 36317407]
Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi:10.1186/s13601-015-0073-8 [PubMed 26339470]
Shahin L, Patel KM, Heydari MK, Kesselman MM. Hyperuricemia and cardiovascular risk. Cureus. 2021;13(5):e14855. doi:10.7759/cureus.14855 [PubMed 34104597]
Sharma R, Abrol D, Deep Singh G, Angurana SL. Febuxostat versus allopurinol for the prevention and treatment of hyperuricemia in chronic myelogenous leukemia with hyperleucocytosis. JK Science. 2016;18(1):12-15.
Shin A, Choi SR, Han M, et al. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: update with accumulated use of febuxostat. Semin Arthritis Rheum. 2022;56:152080. doi:10.1016/j.semarthrit.2022.152080 [PubMed 35973263]
Singh JA, Cleveland JD. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. Ann Rheum Dis. 2020;79(4):529-535. doi:10.1136/annrheumdis-2019-216917 [PubMed 32024648]
Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-335. [PubMed 23868909]
Spina M, Nagy Z, Ribera JM, et al; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155-2161. doi:10.1093/annonc/mdv317 [PubMed 26216382]
Su CY, Shen LJ, Hsieh SC, Lin LY, Lin FJ. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. Mayo Clin Proc. 2019;94(7):1147-1157. doi:10.1016/j.mayocp.2019.03.001 [PubMed 31272565]
Takai M, Yamauchi T, Ookura M, et al. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study. Anticancer Res. 2014;34(12):7287-7296. [PubMed 25503162]
Tamura K, Kawai Y, Kiguchi T, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016;21(5):996-1003. doi:10.1007/s10147-016-0971-3 [PubMed 27017611]
Tana T, Vadas P. Febuxostat desensitization in a patient with previous Stevens-Johnson syndrome and HLA-B*58:01 genotype. J Rheumatol. 2019;46(9):1250-1251. doi:10.3899/jrheum.181051 [PubMed 31308200]
Uloric (febuxostat) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; April 2023.
Uloric (febuxostat) [product monograph]. Oakville, Ontario, Canada: Takeda Canada Inc; September 2019.
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-1210. doi:10.1056/NEJMoa1710895 [PubMed 29527974]
Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32(14):2386-2397. doi:10.1016/j.clinthera.2011.01.008 [PubMed 21353107]
Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324. [PubMed 16707532]

Topic 9079 Version 296.0

خرید پکیج

Febuxostat: Drug information